Trial Profile
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of MEDI-524, a Humanized Enhanced Potency Monoclonal Antibody Against Respiratory Syncytial Virus (RSV), in Children with Hemodynamically Significant Congenital Heart Disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 23 Dec 2021
Price :
$35
*
At a glance
- Drugs Motavizumab (Primary) ; Palivizumab
- Indications Respiratory syncytial virus infections
- Focus Adverse reactions
- Sponsors MedImmune
- 09 Oct 2020 Status changed from recruiting to completed.
- 24 Nov 2005 New trial record.